| Mrs Lillie Mae Dean, REGNURSEPRACTIONER | |
|
10101 Renner Blvd, Lenexa, KS 66219-9752 | |
| (913) 577-1641 | |
| (913) 859-6887 |
| Full Name | Mrs Lillie Mae Dean |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Obstetrics & Gynecology |
| Location | 10101 Renner Blvd, Lenexa, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043645062 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LX0001X | Nurse Practitioner - Obstetrics & Gynecology | 288380 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Lillie Mae Dean, REGNURSEPRACTIONER 10101 Renner Blvd, Lenexa, KS 66219 Ph: (913) 577-1641 | Mrs Lillie Mae Dean, REGNURSEPRACTIONER 10101 Renner Blvd, Lenexa, KS 66219-9752 Ph: (913) 577-1641 |
News Archive
A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.
Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.
Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved a revision to the dosing recommendation to include once-daily dosing of PREZISTA® (darunavir) tablets in combination with ritonavir for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adult patients with no darunavir resistance-associated mutations (DRV RAMs).
› Verified 6 days ago
Eileen Frances Frausto, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 9913 Sunset Dr, Lenexa, KS 66220 Phone: 913-308-5498 | |
Everett G. Bennett Iii, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 11001 Hauser St, Lenexa, KS 66210 Phone: 913-353-4703 Fax: 949-543-2954 | |
Robert Otto, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 7721 Quivira Rd, Lenexa, KS 66216 Phone: 913-706-2508 Fax: 913-248-2808 | |
Hailey Wank, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 11150 Thompson Ave, Lenexa, KS 66219 Phone: 913-850-7500 Fax: 913-850-7579 | |
Jessica Michelle Croft, MSN, APRN, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 15928 W 84th Ter, Lenexa, KS 66219 Phone: 913-653-3356 | |
Olivia Ann Keenan, DNP, APRN, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 7825 Woodstone Ln, Lenexa, KS 66217 Phone: 785-640-8818 |